doxorubicin (PLD) seems to significantly reduce the incidence of HSRs attributable to carboplatin compared with administering carboplatin as a single agent or in combination with paclitaxel. 31 , 32 The effect of PLD on reducing carboplatin-related infusion
Search Results
Matthieu Picard, Ursula A. Matulonis, and Mariana Castells
Neelima Vidula, Leif W. Ellisen, and Aditya Bardia
III study compared veliparib with carboplatin and paclitaxel followed by maintenance veliparib versus chemotherapy in germline BRCA1/2 -mutant HER2-negative advanced breast cancer. 18 Median PFS improved from 12.6 to 14.5 months with the addition of
Dipesh Uprety and David E. Marinier
used for concurrent CRT, including cisplatin/etoposide, carboplatin/paclitaxel, cisplatin/vinblastine, and, for nonsquamous pathology, carboplatin or cisplatin with pemetrexed. 7 The carboplatin/paclitaxel regimen is given weekly with radiation therapy
Presented by: Melinda L. Telli and William J. Gradishar
1mic disease. 3 Treatment with weekly paclitaxel for 12 cycles plus trastuzumab for 1 year led to a 7-year OS rate of 95%, with only 4 of 406 patients experiencing distant recurrences. The subsequent ATEMPT trial evaluated the newer agent ado
Feng Lin, Jinlin Song, Melissa Pavilack, Jipan Xie, Catherine Fernan, Ahmed Noman, and Winghan Jacqueline Kwong
patients who used TBR as 1L, 130 initiated 2L treatment and trastuzumab was used again as 2L in 72 patients. The most common regimens used in 2L post 1L TBR were paclitaxel + ramucirumab (15.4%), FOLFOX + trastuzumab (11.5%), and capecitabine + trastuzumab
Robert J. Morgan Jr, Ronald D. Alvarez, Deborah K. Armstrong, Robert A. Burger, Lee-may Chen, Larry Copeland, Marta Ann Crispens, David M. Gershenson, Heidi J. Gray, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Lainie Martin, Ursula A. Matulonis, David M. O’Malley, Richard T. Penson, Matthew A. Powell, Steven W. Remmenga, Paul Sabbatini, Joseph T. Santoso, Julian C. Schink, Nelson Teng, Theresa L. Werner, Mary A. Dwyer, and Miranda Hughes
measuring less than 1 cm after debulking, survival was increased by 16 months after IP therapy using cisplatin/paclitaxel when compared with standard intravenous therapy (65.6 vs 49.7 months; P =.03). 15 Recent long-term follow-up data have confirmed this
NCCN Guidelines Insights: Cervical Cancer, Version 1.2020
Featured Updates to the NCCN Guidelines
Nadeem R. Abu-Rustum, Catheryn M. Yashar, Sarah Bean, Kristin Bradley, Susana M. Campos, Hye Sook Chon, Christina Chu, David Cohn, Marta Ann Crispens, Shari Damast, Christine M. Fisher, Peter Frederick, David K. Gaffney, Robert Giuntoli II, Ernest Han, Warner K. Huh, John R. Lurain III, Andrea Mariani, David Mutch, Christa Nagel, Larissa Nekhlyudov, Amanda Nickles Fader, Steven W. Remmenga, R. Kevin Reynolds, Rachel Sisodia, Todd Tillmanns, Stefanie Ueda, Renata Urban, Emily Wyse, Nicole R. McMillian, and Angela D. Motter
doublet and triplet chemotherapy regimens (ie, cisplatin/paclitaxel, carboplatin/paclitaxel, topotecan/paclitaxel, and topotecan/paclitaxel/bevacizumab) were restratified according to the NCCN Categories of Preference. In addition, emerging data on a new
Presented by: Eileen M. O’Reilly
gemcitabine plus albumin-bound (nab)-paclitaxel, based on the disappointing results of the recent APACT trial. 7 Consensus is lacking for adjuvant chemotherapy plus radiation, which is being studied in the phase III RTOG 0848 trial and for which results are
Philip E. Lammers and Leora Horn
randomized phase III trial comparing carboplatin/paclitaxel with or without bevacizumab in 878 patients with recurrent or advanced nonsquamous NSCLC. 9 Improvements in median overall survival (OS), median progression-free survival (PFS), and response rate
Kohei Shitara and Atsushi Ohtsu
care was associated with significantly improved OS in patients with disease progression on first-line chemotherapy. 9 Moreover, ramucirumab plus paclitaxel chemotherapy significantly increased OS compared with paclitaxel alone in patients after first
